Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

@inproceedings{McMillin2010TumorCB,
  title={Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity},
  author={Douglas W. McMillin and Jake Delmore and Ellen Weisberg and Joseph M. Negri and David Geer and Steffen Klippel and Nicholas S. Mitsiades and Robert L. Schlossman and Nikhil C. Munshi and Andrew L Kung and James D Griffin and Paul G Richardson and Kenneth C. Anderson and Constantine Mitsiades},
  booktitle={Nature Medicine},
  year={2010}
}
Conventional anticancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, we developed the tumor cell–specific in vitro bioluminescence imaging (CS-BLI) assay. Tumor cells (for example, myeloma, leukemia and solid tumors… CONTINUE READING
  • Blog articles referencing this paper

  • Presentations referencing similar topics